KRAS and colorectal carcinoma: This mechanistic insight provides a molecular reason for the selective vulnerability of KRAS-mutant CRC to metformin and strongly suggests that low MATE1 expression levels are a promising predictive biomarker, particularly alongside KRAS status, for identifying patients who can accumulate sufficient intracellular metformin to achieve therapeutic effects (Figure 1).